Program Coordinator Dr Mark Blaskovich has been busy attending AMR meetings across Australia. Latest blog by Dr Blaskovich.
It’s time we were clear about how we talk about antibiotic resistance (AMR). A recent Comment piece in Nature is urging those in the antimicrobial resistance space to standardise terminology to maximise understanding of the issue and stimulate action.
“Many of the terms routinely used to describe the AMR are misunderstood, interpreted differently or loaded with unhelpful connotations.”
ECCMID is the largest annual clinically focused infectious disease meeting in Europe, attracting a record breaking 12,494 delegates from 126 countries worldwide.
Although ECCMID is a profoundly clinical focused meeting, our CO-ADD team found some great inspiration from talks on biofilm eradication, diagnostic technologies and general updates on the spread of infectious diseases throughout Europe and beyond. This year’s meeting had a heavy focus on the challenges of successfully treating biofilms (both bacterial and fungal), and diagnostics for bacterial, fungal and viral identification.
And what a conference it was! On 3 – 5 April in Brisbane, we hosted global leaders and experts in the antimicrobial resistance (AMR) space - including researchers, politicians, policymakers and advocates - for the Solutions for Drug-Resistant Infections conference (SDRI 2017).
CO-ADD tests compounds against five of the top pathogens listed on the WHO priority list for R&D of new antibiotics: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus, as well as the fungi Cryptococcus neoformans and Candida albicans.
“We welcome the published list of priority pathogens to be worked on from the World Health Organization. Our research targets five of the pathogens listed, including the three most critical. This will be a vital tool that will guide antibiotic research and drug discovery for the future,” said CO-ADD Dr Mark Blaskovich.
CO-ADD media enquiries: email@example.com; +61 (0) 733462389